In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback